Cy­tori shares surge on mixed re­sults for its PhI erec­tile dys­func­tion study

7 years ago
R&D

Chi­na to cut can­cer drug prices; Nim­bus nabs Gilead­'s Adri­an Ray to serve as SVP of dis­cov­ery bi­ol­o­gy

7 years ago
News Briefing

Cash-strapped Reg­u­lus braces for dras­tic down­siz­ing while hit­ting the brakes on lead pro­grams

7 years ago
R&D
Pharma

Ver­tex CEO to UK Prime Min­is­ter: You’re de­valu­ing lives, pass­ing up a great of­fer and threat­en­ing the coun­try’s ...

7 years ago
Pharma

Years in the un­mak­ing, CTI’s Pix­u­vri fails a piv­otal PhI­II com­bo study for lym­phoma — can it re­main on the ...

7 years ago
R&D

Pop­u­lar ke­to di­et set to be test­ed in hu­mans to see if it can amp up ef­fect of weak PI3K drugs

7 years ago
R&D

Fo­cused on re­build­ing the pipeline, Ax­o­van­t's new crew as­sem­bles an­oth­er pre­clin­i­cal gene ther­a­py deal

7 years ago
R&D
Pharma

Abing­worth lines up $315M to bet on a new gen­er­a­tion of transat­lantic biotechs

7 years ago
Financing

Cash-rich Cam­bridge start­up Ru­bius to build $155M cell ther­a­py man­u­fac­tur­ing site in Rhode Is­land

7 years ago
Startups

Ap­peas­ing ac­tivist in­vestors, Iron­wood cuts 40 staffers at the start of com­pa­ny split

7 years ago
People
R&D

Ac­celeron poach­es ex-Abl­ynx CMO Robert Zeldin; Deb­o­rah Dun­sire leaves for Lund­beck­'s top job af­ter XTu­it im­plo­sion

7 years ago
Peer Review

That Alzheimer's drug that flunked a PhII? On sec­ond look, Bio­gen/Ei­sai say it's a win­ner

7 years ago
R&D

With tech from Spin­raza­'s mak­er, French start­up Dy­nacure gets $55M to tack­le neu­ro­mus­cu­lar dis­ease

7 years ago
Financing
Startups

New Jer­sey's bait worked: Af­ter promise of $40M in in­cen­tives, Te­va is mov­ing its HQ

7 years ago
Pharma

Trump in­vites phar­ma heads to pri­vate din­ner dur­ing Lon­don vis­it, a trip that's in­spir­ing tens of thou­sands to ...

7 years ago
People
Pharma

FDA OKs Xeomin in fourth in­di­ca­tion; Nextbi­otix rais­es $8M for mi­cro­bio­me tech

7 years ago
News Briefing

Take­da posts 'for-sale' sign on com­pa­ny's an­ces­tral home in Os­a­ka in ef­fort to fund Shire buy­out

7 years ago
Deals

THC ther­a­py tanks in PhI, send­ing Zyner­ba's stock tum­bling yet again

7 years ago
R&D

An­oth­er IPO fren­zy? Two US biotechs head to Hong Kong for a pub­lic mar­ket de­but

7 years ago
Financing
China

Mer­ck scores pri­or­i­ty re­view Keytru­da in squa­mous NSCLC; Syn­thet­ic Ge­nomics spin­out SGI-DNA gets new CEO

7 years ago
News Briefing

Hong Kong ex­change picks up steam with two biotech IPOs from In­novent, Mi­cuRx

7 years ago
Financing
China

No­var­tis dumps world­wide rights to an Aveo drug, and the lit­tle biotech is not hap­py with them

7 years ago
R&D

Re­gen­eron, Sanofi show re­straint on Dupix­ent price hike, but Pfiz­er’s hard charge con­tin­ues to spur calls for a ...

7 years ago
Bioregnum
Opinion

Catal­ent inks $133M deal to buy Ju­niper Phar­ma­ceu­ti­cals, adding UK de­vel­op­ment ser­vices

7 years ago
Deals
Outsourcing
First page Previous page 1027102810291030103110321033 Next page Last page
A service from the Financial Times